18:22 , Jan 12, 2018 |  BC Week In Review  |  Company News

Generex grants Shenzhen rights in China to cancer vaccine

Antigen Express Inc., a subsidiary of Generex Biotechnology Corp. (OTCQB:GNBT), granted Shenzhen BioScien Pharmaceuticals Co. Ltd. (Shenzhen, China) rights to develop and commercialize Ii-Key/HER2/neu cancer vaccine (AE37) in Taiwan and China, including Hong Kong and...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

Ii-Key/HER2/neu cancer vaccine: Interim Phase II data

Interim data from a single-blind, international Phase II trial in node-positive or high-risk, node-negative breast cancer patients with any degree of HER2 expression showed that AE37 plus GM-CSF reduced the risk of relapse by 42%...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Generex cancer, drug delivery news

Generex provided an update on its plans to spin out its wholly-owned subsidiary, Antigen Express Inc. , and said several merger opportunities, including shell companies and operating biotechs with synergistic properties, are being reviewed. The...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Generex drug delivery news

Generex said it sold two non-essential commercial real estate properties for just over C$1 million ($1 million) as part of a reorganization plan. Generex said the transaction will allow the company to concentrate on its...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Generex management update

Generex Biotechnology Corp. (OTCBB:GNBT), Toronto, Ontario   Business: Drug delivery   Hired: Jos van der Woert as CEO of Generex's Antigen Express Inc. subsidiary following its spin out, formerly general manager and group VP of...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Generex drug delivery news

Generex said it plans to spin out its wholly-owned subsidiary, Antigen Express Inc. and its immunotherapeutic vaccines, including the Ii-Key/HER2/neu cancer vaccine ( AE37 ), which is in Phase II testing to prevent breast cancer...
08:00 , Feb 8, 2010 |  BioCentury  |  Finance

Cancer immunotherapy mentor

Mentor Capital Inc. (Pink:MNTR) has collected $126.3 million in commitments to invest in its Cancer Immunotherapy Index, which was launched in July 2009. The company has received the first seed tranche of $1.2 million from...
07:00 , May 4, 2009 |  BioCentury  |  Product Development

Vaccine Manufacturing Technologies

Vaccine Manufacturing Technologies Company Vaccine manufacturing technology Avir Green Hills Biotechnology AG deltaFLU technology uses tissue cultures to produce vaccine Bacilligen Inc. Bacterial cells Baxter International Inc. (NYSE:BAX) Vero cells Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) /...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Company News

Generex, Pevion Biotech deal

The partners will use Pevion's virosome technology and Generex's Antigen Express Inc. subsidiary's immunotherapeutic peptides to develop vaccines and immunotherapeutics to treat cancer. Pevion's technology enhances the potency of antigens, and Antigen's technology increases the...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

University of Massachusetts regulatory update

The university received U.S. Patent No. 5,620,896 covering the use of a DNA vaccine encoding a rotavirus capsid protein to immunize humans and other animals against rotavirus infection. Researchers at the university's Medical Center are...